{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:24:32Z","timestamp":1790475872703,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alimera Sciences, Inc. USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Uncontrolled non-infectious uveitis affecting the posterior segment (NIU-PS) can lead to vision loss due to repeated bouts of inflammation and consequent tissue damage. Patients with chronic NIU-PS who experience recurrent uveitis after being treated with systemic and short-acting local corticosteroids may benefit from the sustained-release 0.18-mg fluocinolone acetonide implant (FAi).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this case series, 18 eyes with chronic, recurrent NIU-PS and cystoid macular edema (CME) treated with the 0.18-mg FAi were analyzed retrospectively. Data on patient demographics, clinical history, previous and concomitant treatments for uveitis recurrence, time to and number of uveitis recurrences, intraocular pressure (IOP), central subfield thickness (CST), and visual acuity (VA) were collected and summarized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A majority of patients (14\/15 [93%]) had a history of ocular surgery, largely cataract extraction, and all developed chronic and recurrent NIU-PS and CME. At baseline, patients had a mean age of 72 years (range: 46 to 93), were 53% male, and had a mean duration of NIU-PS of 3 years (range: 1 to 19). Patients were followed for an average of 16.5 months (range: 2 to 42.5 months) post FAi. Eleven of the 18 eyes (61%) had\u2009\u2265\u20095 recurrences of uveitis since diagnosis, with an average time to recurrence of approximately 12 weeks (range: 1 to 27). All eyes treated with the 0.18-mg FAi showed reduced NIU-PS recurrence and visual and anatomical improvement, as measured by VA and CST, respectively. Two eyes had an IOP elevation that was managed with topical therapy, and one eye was treated with topical prednisolone for additional inflammation management. Two eyes required adjunct therapy with short-acting intravitreal corticosteroids at 7 and 16 weeks for NIU-PS recurrence after 0.18-mg FAi insertion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>After receiving the 0.18-mg FAi, eyes with uncontrolled NIU-PS had sustained resolution of CME and inflammation with limited need for supplementary steroid drops or injections and minimal steroid class-specific adverse effects; none required incisional IOP-lowering surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-024-00427-9","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:02:14Z","timestamp":1726725734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fluocinolone acetonide 0.18-mg implant for treatment of recurrent inflammation due to non-infectious uveitis: a case series of 15 patients"],"prefix":"10.1186","volume":"14","author":[{"given":"Robert A.","family":"Sisk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Kiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton M.","family":"Kolomeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Kitchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"427_CR1","doi-asserted-by":"publisher","unstructured":"Chen SC, Sheu SJ (2017) Recent advances in managing and understanding uveitis. F1000Res 6:280. https:\/\/doi.org\/10.12688\/f1000research.10587.1","DOI":"10.12688\/f1000research.10587.1"},{"key":"427_CR2","doi-asserted-by":"crossref","unstructured":"Suttorp-Schulten MS, Rothova A (1996) The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 80(9):844\u2013848","DOI":"10.1136\/bjo.80.9.844"},{"key":"427_CR3","doi-asserted-by":"crossref","unstructured":"Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88(9):1159\u20131162","DOI":"10.1136\/bjo.2003.037226"},{"key":"427_CR4","doi-asserted-by":"crossref","unstructured":"Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD (2019) Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol 13:1761\u20131777","DOI":"10.2147\/OPTH.S180580"},{"key":"427_CR5","doi-asserted-by":"crossref","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509\u2013516","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"427_CR6","doi-asserted-by":"crossref","unstructured":"Bajwa A, Osmanzada D, Osmanzada S et al (2015) Epidemiology of uveitis in the Mid-atlantic United States. Clin Ophthalmol 9:889\u2013901","DOI":"10.2147\/OPTH.S80972"},{"key":"427_CR7","doi-asserted-by":"crossref","unstructured":"Joltikov KA, Lobo-Chan AM (2021) Epidemiology and risk factors in non-infectious uveitis: a systematic review. Front Med (Lausanne) 8:695904","DOI":"10.3389\/fmed.2021.695904"},{"key":"427_CR8","doi-asserted-by":"crossref","unstructured":"Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111(3):491\u2013500","DOI":"10.1016\/j.ophtha.2003.06.014"},{"key":"427_CR9","doi-asserted-by":"crossref","unstructured":"Thorne JE, Suhler E, Skup M et al (2016) Prevalence of noninfectious uveitis in the United States: a claims-based analysis. JAMA Ophthalmol 134(11):1237\u20131245","DOI":"10.1001\/jamaophthalmol.2016.3229"},{"key":"427_CR10","doi-asserted-by":"crossref","unstructured":"Bodaghi B, Cassoux N, Wechsler B et al (2001) Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Med (Baltim) 80(4):263\u2013270","DOI":"10.1097\/00005792-200107000-00005"},{"key":"427_CR11","doi-asserted-by":"crossref","unstructured":"Pavesio C, Heinz C (2022) Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis. Eye (Lond) 36(6):1231\u20131237","DOI":"10.1038\/s41433-021-01608-9"},{"key":"427_CR12","doi-asserted-by":"crossref","unstructured":"Testi I, Pavesio C (2019) Preliminary evaluation of YUTIQ\u2122 (fluocinolone acetonide intravitreal implant 0.18\u00a0mg) in posterior uveitis. Ther Deliv 10(10):621\u2013625","DOI":"10.4155\/tde-2019-0051"},{"key":"427_CR13","unstructured":"YUTIQ (2023) Prescribing information. Alimera Sciences, Inc. https:\/\/www.yutiq.com\/pi\/"},{"key":"427_CR14","doi-asserted-by":"crossref","unstructured":"Chang PY (2022) Use of fluocinolone acetonide intravitreal implant to manage chronic panuveitis for long-term inflammatory control without interfering with systemic immunity. Digit J Ophthalmol 28(4):119\u2013125","DOI":"10.5693\/djo.02.2022.10.002"},{"key":"427_CR15","doi-asserted-by":"crossref","unstructured":"Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG (2019) Update in treatment of uveitic macular edema. Drug Des Devel Ther 13:667\u2013680","DOI":"10.2147\/DDDT.S166092"},{"key":"427_CR16","unstructured":"Harapriya A, Anthony E (2019) Managing cataract surgery in patients with uveitis. Community Eye Health 31(104):82\u201383"},{"key":"427_CR17","doi-asserted-by":"crossref","unstructured":"Schein OD, Cassard SD, Tielsch JM, Gower EW (2012) Cataract surgery among Medicare beneficiaries. Ophthalmic Epidemiol 19(5):257\u2013264","DOI":"10.3109\/09286586.2012.698692"},{"key":"427_CR18","doi-asserted-by":"crossref","unstructured":"Bajraktari G, Juki\u0107 T, Kalauz M, Oroz M, Radolovi\u0107 Berteti\u0107 A, Vukojevi\u0107 N (2023) Early and late complications after cataract surgery in patients with uveitis. Med (Kaunas) 59(10):1877","DOI":"10.3390\/medicina59101877"},{"key":"427_CR19","doi-asserted-by":"crossref","unstructured":"Jevnikar K, Po\u010dkar S, Umek L, Rothova A, Valentincic NV (2023) Prognostic factors of cataract surgery in patients with uveitis. Int Ophthalmol 43(12):4605\u20134612","DOI":"10.1007\/s10792-023-02860-6"},{"key":"427_CR20","doi-asserted-by":"crossref","unstructured":"Chu CJ, Dick AD, Johnston RL, Yang YC, Denniston AK, UK Pseudophakic Macular Edema Study Group (2017) Cataract surgery in uveitis: a multicentre database study. Br J Ophthalmol 101(8):1132\u20131137","DOI":"10.1136\/bjophthalmol-2016-309047"},{"key":"427_CR21","unstructured":"Shaw E, Patel BC (2023) Complicated cataract. StatPearls, vol 4. StatPearls Publishing, Treasure Island (FL)"},{"key":"427_CR22","doi-asserted-by":"crossref","unstructured":"B\u00e9lair ML, Kim SJ, Thorne JE et al (2009) Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am J Ophthalmol 148(1):128\u201335e2","DOI":"10.1016\/j.ajo.2009.02.029"},{"key":"427_CR23","doi-asserted-by":"crossref","unstructured":"Gaballa A, Kompella UB, Elgarhy O et al (2021) Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res 11:866\u2013893","DOI":"10.1007\/s13346-020-00843-z"},{"key":"427_CR24","doi-asserted-by":"crossref","unstructured":"Jaffe GJ, Pavesio CE, Study I (2020) Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology 127:1395\u20131404","DOI":"10.1016\/j.ophtha.2020.04.001"},{"key":"427_CR25","doi-asserted-by":"crossref","unstructured":"Steeples LR, Pockar S, Jones NP, Leal I (2021) Evaluating the safety, efficacy and patient acceptability of intravitreal fluocinolone acetonide (0.2mcg\/day) implant in the treatment of non-infectious uveitis affecting the posterior segment. Clin Ophthalmol 15:1433\u20131442","DOI":"10.2147\/OPTH.S216912"},{"key":"427_CR26","doi-asserted-by":"crossref","unstructured":"Jaffe GJ, Lin P, Keenan RT, Ashton P (2016) Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology 123:1940\u20131948","DOI":"10.1016\/j.ophtha.2016.05.025"},{"key":"427_CR27","doi-asserted-by":"crossref","unstructured":"Yang Y, Bailey C, Loewenstein A, Massin P (2015) Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina 35(12):2440\u20132449","DOI":"10.1097\/IAE.0000000000000726"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-024-00427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-024-00427-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-024-00427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:03:09Z","timestamp":1726725789000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-024-00427-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["427"],"URL":"https:\/\/doi.org\/10.1186\/s12348-024-00427-9","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective case series was in accordance with good clinical practice protocols and adhered to the tenets of the Declaration of Helsinki. Informed verbal and written consent was obtained from the patients for the publication of this report. Sterling IRB determined our series was exempt from IRB review (reference # 12292-RSisk) due to the low-risk nature of the retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent was requested and obtained from the patients for study inclusion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Robert A. Sisk: consultant for AGTC\/Beacon, Ascidian, EyePoint, Gyroscope, Iveric Bio, Leica Microsystems, Novartis, Orbit Biomedical, Oxular, and RegenxBio.\u00a0Daniel F. Kiernan: speaker\u2019s bureau for Alimera, Allergan\/AbbVie, Bausch & Lomb, Coherus, EyePoint, Harrow, Mallinckrodt, Novartis, Notal Vision, Physician Recommended Nutraceuticals, and Regeneron. Consultant for Allergan\/AbbVie, Bausch + Lomb, Coherus, EyePoint, Mallinckrodt, Physician Recommended Nutraceuticals, and Regeneron. Received grant support from Allergan\/ Abbvie, EyePoint, Gyroscope, and Opthea. David Almeida: consultant for Alcon, Alimera, Allergan\/AbbVie, Genentech, and Regeneron. Has received financial support (funding, grants, research materials, or in-kind services) from Acylerin, Alcon, Alimera, Allergan\/AbbVie, Bausch + Lomb, Bayer, Boehringer Ingelheim, Dutch Ophthalmics, EyePoint, Genentech, Gyroscope, Novartis, Ocugen, Opthea, Regeneron, RegenexBio, Roche, and Samara Vision. Has personal financial interest in Citrus Therapeutics (cofounder), Erie Retina Research (President & CEO), Element: Reading Center (President & CEO), Access for All (Non-profit; chairman of the board), KPeye (President & CEO), React: Research in Advanced Technologies (cofounder & managing partner), and ACT: Applied Clinical Technologies (cofounder and managing partner). Anton M. Kolomeyer: consultant for Alimera, Allergan, Apellis, Biogen, Genentech, Iveric (Astellas), and Regeneron. Speaker for Biogen, Genetech, and Iveric (Astellas).\u00a0David Eichenbaum: consultant for Alimera, Allergan, Annexon, Appelis, Bausch + Lomb, Coherus, Crinetics, Eyepoint, Genentech, IvericBio, Kodiak, Novartis, Ocuphire, Opthea, Outlook, Ocular Therapeutix, RecensMedical, Regeneron, RegenexBio, ReVive, Samsara, and Vestrum\/CorEvitas. Speaker for Allergan, Apellis, Bayer, Genentech, IvericBio, Novartis, and Regeneron. Investigator for 4DMT, Aerie\/Alcon, Alexion, Allegenesis, Annexon, Aviceda, Bayer, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, IvericBio, Janssen, Kodiak, Mylan, NGM, Janssen, Novartis, Ocular Therapeutix, Opthea, RecensMedical, Regeneron, RegenxBio, ONL, and Unity. Holds equity\/ is a stockholder in the Boston Image Reading Center, Janssen, Network Eye, ReVive, and US Retina. Founder of Network Eye.\u00a0John W. Kitchens: consultant for Alcon, Allergan, Alimera, Apellis, Astellas, Bayer, Biogen, Bausch + Lomb, Genentech, Kodiak Bioscience, Notal Vision, Optos, Oculus, Outlook, Regeneron, Roche, and Zeiss. Speaker for Alcon, Bayer, Genentech, and Regeneron. Owns stock in Regeneron.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}